Eli Lilly has brought in billion-dollar revenue from its weight loss drugs -- but short supply has limited the revenue opportunity. The FDA earlier this month recognized Lilly’s progress in ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests ...

Earnings Report 1.454 USD Q3 2024 Earnings Release 10/30/2024 Earnings Report 5.436 USD Q4 2024 Earnings Release 01/30/2025 Earnings Report 5.367 USD Q1 2025 Earnings Release 04/24/2025 Earnings ...

Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call that day with the investment community and ...

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment for diabetes and obesity.

After hours: October 18 at 7:58 PM EDT Loading Chart for LLY ...